Current Clinical Challenges and Emerging Multi-Modal Approaches for the Treatment of Pancreatic Cancer

Fiona Haxho, Manpreet Sambi, Bessi Qorri, William Harless and Myron R. Szewczuk

Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada
ENCYT Technologies, Inc. Membertou, NS, Canada
These authors have contributed equally

^*Correspondance to: William Harless Myron R. Szewczuk 

 PDF  Full Text Review Article | Open Access

Abstract:

Today, emerging therapies must effectively shut down multiple enabling characteristics that drive pancreatic cancer invasion and progression. These therapies include the concomitant suppression of growth factor signaling and anti-apoptotic pathways, immune-derived promoters of tumorigenesis, mechanisms of acquired drug resistance, as well as pro-metastatic signals that facilitate cancer cell migration and successful homing of disseminated tumor cells. Here, we provide an overview of some of the current treatment options available for patients with pancreatic cancer, as well as their limitations. Finally, we review some alternative multi-target strategies that may provide increased efficacy in cancer therapy.

Keywords:

Pancreatic cancer; PDAC; Cancer therapy; Drug resistance; Cancer stem cells; Alternative therapy

Cite the Article:

Haxho F, Sambi M, Qorri B, Harless W, Szewczuk MR. Current Clinical Challenges and Emerging Multi-Modal Approaches for the Treatment of Pancreatic Cancer. Clin Oncol. 2017; 2: 1296.